Telaprevir: Difference between revisions
Citation bot (talk | contribs) |
Carlo Banez (talk | contribs) - tradename information added |
||
| Line 6: | Line 6: | ||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = Incivek |
||
| Drugs.com = {{drugs.com|CDI|telaprevir}} |
| Drugs.com = {{drugs.com|CDI|telaprevir}} |
||
| MedlinePlus = a611038 |
| MedlinePlus = a611038 |
||
Revision as of 15:59, 14 December 2011
 | |
| Clinical data | |
|---|---|
| Trade names | Incivek |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a611038 |
| License data |
|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.129.857 |
| Chemical and physical data | |
| Formula | C36H53N7O6 |
| Molar mass | 679.85 g/mol g·mol−1 |
| |
  (what is this?) (verify) | |
Telaprevir (VX-950), marketed as the brand name Incivek, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors.[1] Specifically, telaprevir inhibits the hepatitis C virus NS3.4A serine protease.[2]
In a randomized controlled trial of patients in whom standard treatment with peginterferon alfa-2a and ribavirin had failed, repeat treatment with the addition of telaprevir was more likely to have a sustained response than repeat treatment with peginterferon alfa-2a and ribavirin alone.[3]
Telaprevir is the first hepatitis C drug that has demonstrated activity in patients who have failed prior therapy.[4]
On April 28, 2011, the FDA Antiviral Drugs Advisory Committee voted 18-0 to recommend approval telaprevir for people with genotype 1 chronic hepatitis C. The committee reviewed clinical trial data (including findings from the Phase 3 ADVANCE, ILLUMINATE, and REALIZE studies) showing that combining telaprevir with pegylated interferon/ribavirin produced a higher cure rate -- and in less time -- than standard therapy alone. This improvement is most notable for hard-to-treat patients including those with HCV genotype 1, people with liver cirrhosis, and those who did not respond to a prior course of interferon-based therapy. Merck's boceprevir, also a new anti hepatitis C drug, was given a positive recommendation by the same committee, on the previous day.[5] Telaprevir was fully approved for use in the United States in May 2011.[6]
References
- ^ Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). "Telaprevir". Drugs of the Future. 32 (9): 788. doi:10.1358/dof.2007.032.09.1138229.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Lin C, Kwong AD, Perni RB (2006). "Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease". Infect Disord Drug Targets. 6 (1): 3–16. doi:10.2174/187152606776056706. PMID 16787300.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ McHutchison JG, Manns MP, Muir AJ; et al. (2010). "Telaprevir for previously treated chronic HCV infection". N. Engl. J. Med. 362 (14): 1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ Irena Melnikova (2008). "Hepatitis C therapies". Nature Reviews Drug Discovery. 7 (10): 799–800. doi:10.1038/nrd2661.
- ^ FDA recommends approval for Telaprevir and Boceprevir
- ^ FDA Approves Telaprevir for HCV, May 23, 2011